Heron Therapeutics reported increased net product sales of $114.3M for the nine months ended September 30, 2025, driven by 69.2% growth in Acute Care products (ZYNRELEF and APONVIE). However, the quarterly net loss widened significantly to ($17.5M) in Q3, influenced primarily by an $11.3M loss recognized from major debt extinguishment activities during the period.
Capital Structure Overhaul: In August 2025, Heron executed significant financing, raising $27.7M in gross proceeds via a private placement of common stock and Series A Convertible Preferred Stock. Concurrently, the company s
...